Abstract
Objectives: Congenital cystic adenomatoid malformation (CCAM) is a rare lesion of the developing fetal lung consisting of increased cell proliferation in the bronchial structures with lack of differentiation of the alveoli. Pregnancies may be at an increased risk for perinatal loss with type III CCAM. The purpose of this paper is to present our experience with the management of complicated types II and III CCAM with a novel technique: percutaneous ultrasound-guided fetal sclerotherapy (FST). Methods: Three patients were referred with type II-III CCAM. Poor prognostic factors included hydrops, severe mediastinal shift, polyhydramnios and early gestational age (<26 weeks). Patients signed an informed consent. FST was performed with percutaneous injection of Ethamolin (ethanolamine oleate) or Polidocanol (aethoxysklerol) under ultrasound guidance using a 22-gauge needle. Results: Resolution of hydrops and of the mass effect was observed in all cases without any complications. All patients were delivered at term. Conclusions: Fetal sclerotherapy is a novel approach to the management of complicated type II-III CCAM. Further studies are indicated to assess the risks and benefits of this innovative technique.
| Original language | English |
|---|---|
| Pages (from-to) | 237-240 |
| Number of pages | 4 |
| Journal | Fetal Diagnosis and Therapy |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| State | Published - Oct 1 2008 |
Fingerprint
Keywords
- Cystic congenital adenomatoid malformation
- Ethamolin (ethanolamine oleate)
- Fetal hydrops
- Fetal therapy
- Lung mass
- Polidocanol (aethoxysklerol)
- Ultrasound
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Pediatrics, Perinatology, and Child Health
- Embryology
- Radiology Nuclear Medicine and imaging
Cite this
Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung. / Bermúdez, Carlos; Pérez-Wulff, Juan; Arcadipane, Mauricio; Bufalino, Gesualdo; Gómez, Libardo; Flores, Luis; Sosa, Cristian; Bornick, Patricia W.; Kontopoulos, Eftichia; Quintero, Rubén A.
In: Fetal Diagnosis and Therapy, Vol. 24, No. 3, 01.10.2008, p. 237-240.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung
AU - Bermúdez, Carlos
AU - Pérez-Wulff, Juan
AU - Arcadipane, Mauricio
AU - Bufalino, Gesualdo
AU - Gómez, Libardo
AU - Flores, Luis
AU - Sosa, Cristian
AU - Bornick, Patricia W.
AU - Kontopoulos, Eftichia
AU - Quintero, Rubén A.
PY - 2008/10/1
Y1 - 2008/10/1
N2 - Objectives: Congenital cystic adenomatoid malformation (CCAM) is a rare lesion of the developing fetal lung consisting of increased cell proliferation in the bronchial structures with lack of differentiation of the alveoli. Pregnancies may be at an increased risk for perinatal loss with type III CCAM. The purpose of this paper is to present our experience with the management of complicated types II and III CCAM with a novel technique: percutaneous ultrasound-guided fetal sclerotherapy (FST). Methods: Three patients were referred with type II-III CCAM. Poor prognostic factors included hydrops, severe mediastinal shift, polyhydramnios and early gestational age (<26 weeks). Patients signed an informed consent. FST was performed with percutaneous injection of Ethamolin (ethanolamine oleate) or Polidocanol (aethoxysklerol) under ultrasound guidance using a 22-gauge needle. Results: Resolution of hydrops and of the mass effect was observed in all cases without any complications. All patients were delivered at term. Conclusions: Fetal sclerotherapy is a novel approach to the management of complicated type II-III CCAM. Further studies are indicated to assess the risks and benefits of this innovative technique.
AB - Objectives: Congenital cystic adenomatoid malformation (CCAM) is a rare lesion of the developing fetal lung consisting of increased cell proliferation in the bronchial structures with lack of differentiation of the alveoli. Pregnancies may be at an increased risk for perinatal loss with type III CCAM. The purpose of this paper is to present our experience with the management of complicated types II and III CCAM with a novel technique: percutaneous ultrasound-guided fetal sclerotherapy (FST). Methods: Three patients were referred with type II-III CCAM. Poor prognostic factors included hydrops, severe mediastinal shift, polyhydramnios and early gestational age (<26 weeks). Patients signed an informed consent. FST was performed with percutaneous injection of Ethamolin (ethanolamine oleate) or Polidocanol (aethoxysklerol) under ultrasound guidance using a 22-gauge needle. Results: Resolution of hydrops and of the mass effect was observed in all cases without any complications. All patients were delivered at term. Conclusions: Fetal sclerotherapy is a novel approach to the management of complicated type II-III CCAM. Further studies are indicated to assess the risks and benefits of this innovative technique.
KW - Cystic congenital adenomatoid malformation
KW - Ethamolin (ethanolamine oleate)
KW - Fetal hydrops
KW - Fetal therapy
KW - Lung mass
KW - Polidocanol (aethoxysklerol)
KW - Ultrasound
UR - http://www.scopus.com/inward/record.url?scp=50049125834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50049125834&partnerID=8YFLogxK
U2 - 10.1159/000151345
DO - 10.1159/000151345
M3 - Article
C2 - 18753764
AN - SCOPUS:50049125834
VL - 24
SP - 237
EP - 240
JO - Fetal Diagnosis and Therapy
JF - Fetal Diagnosis and Therapy
SN - 1015-3837
IS - 3
ER -